Med. praxi. 2020;17(4):241-246 | DOI: 10.36290/med.2020.045

Recognizing and treating sarcoidosis

MUDr. Monika ®urková, Ph.D.1, MUDr. Vladimíra Loą»áková, Ph.D.1, MUDr. Petr Jakubec, Ph.D.1, prof. MUDr. Vítězslav Kolek, DrSc., doc. Dr. Ing. Eva Kriegová2
1 Klinika plicních nemocí a TBC, LF UP a FN Olomouc
2 Ústav imunologie, LF UP a FN Olomouc

Sarcoidosis is a multisystem granulomatous disease of unknown aetiology that typically affects middle-aged and elderly individuals, most commonly women over 40 years of age. The symptoms that a primary care physician may encounter can be very non-specific. The most characteristic complaints occur in the acute form of the disease, Löfgren syndrome, presenting with a typical bilateral hilar lymphadenopathy detected on chest skiagram, a negative tuberculin test, and an eruption of erythema nodosum in the crural region, often accompanied by bilateral arthritis of the talocrural joint. Löfgren syndrome is usually associated with a good prognosis, with most cases developing spontaneous remission of the disease. When this disease is suspected, an additional chest skiagram is indicated and, in the case of a pathological finding, it is advisable to refer the patient to a pulmonologist.

Keywords: pulmonary sarcoidosis, extrapulmonary involvement, diagnosis, treatment.

Published: September 25, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®urková M, Loą»áková V, Jakubec P, Kolek V, Kriegová E. Recognizing and treating sarcoidosis. Med. praxi. 2020;17(4):241-246. doi: 10.36290/med.2020.045.
Download citation

References

  1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WA SOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160: 736-755.
  2. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63(11): 1-58. Go to original source...
  3. Baughman RP, Culver DA, Judson MA. A Concise Review of Pulmonary Sarcoidosis. ARJCCM, 2011; 183: 573-581. Go to original source...
  4. Kolek V, et al. Sarkoidóza. Známé a neznámé. Grada: Praha; 1998.
  5. Arkema EV, Grunewald J, Kullberg S, et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Resp J, 2016; 48: 1690-1699. Go to original source... Go to PubMed...
  6. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thor Soc. 2016; 13(8) 201511-760OC. Go to original source...
  7. Pastorová B, Kolek V, ®urková M, et al. Stud Pneumol Pthiseol 2018; 78: 107-111.
  8. Hunninghake GW, Crystal DG. Pulmonary sarcoidosis. A disorder mediated by excess helper T-lymphocyte activity at sites of disease. N. Engl. J. Med. 1981; 305: 429-434. Go to original source...
  9. Facco M, Cabrelle A, Teramo A. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011; 66: 144-150. Go to original source...
  10. Huang H, Lu Z, Jiang C. Imbalance between Th17 and Regulatory T-Cells in Sarcoidosis. Int. J. Mol. Sci. 2013; 14: 21463-21473. Go to original source... Go to PubMed...
  11. Costabel U, Bross KJ, Guzman J, Nilles A, Ruhle KH, Matthys H. Predictive value of bronchoalveolar T-cell subsets for course of pulmonary sarcoidosis. Ann NY Acad Sci.1986; 465: 418-423. Go to original source... Go to PubMed...
  12. Baughman RP, Judson MA, Wells A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoid Vasc Dif Lung Dis 2017; 34: 280-282.
  13. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus study. Respiratory Medicine, 2010; 104: 717-723. Go to original source...
  14. Baughman RP, Winget D, Lower E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcs Vasc Diff Lung Dis 2000; 17: 60-66.
  15. Baughman RP, Shipley R, Desai S. Changes in chest rentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2006; 136: 526-535. Go to original source...
  16. Sodhi M, Pearson K, White ES, et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respiratory Medicine. 2009; 103: 268-273. Go to original source...
  17. Pirfenidone for Progressive Fibrotic Sarcoidosis(PirFS) - full text na https://clinicaltrials.gov /ct2/show/NCT03260556
  18. Kolek V, et al. Sarkoidóza, nemoc mnoha tváří. Maxdorf 2019.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.